Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

Abstract Background In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored the potential of enhancing ccRCC treatment by concurrently using CXCR2 i...

詳細記述

書誌詳細

出版年:	Journal of Experimental & Clinical Cancer Research
主要な著者:	Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, Jerome Durivault, Frederic Luciano, Delphine Borchiellini, Julie Le Du, Leticia Christina Pires Gonçalves, Patrick Auberger, Rachid Benhida, Lisa Kinget, Benoit Beuselinck, Cyril Ronco, Gilles Pagès, Maeva Dufies
フォーマット:	論文
言語:	英語
出版事項:	BMC 2024-03-01
主題:	Renal Cell Carcinoma M2 tumor associated macrophages Immunotherapies resistance CXCR2 inhibitors Nivolumab Ipilimumab
オンライン･アクセス:	https://doi.org/10.1186/s13046-024-02984-2